By using IL-17RA−/−mice, the authors of one study reported that IL-17RA signaling regulated liver injury in the progression of NAFLD; the neutralization of IL-17A, meanwhile, significantly reduced obesity-driven hepatocellular damage. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.